Protara Therapeutics (TARA) Long-Term Deferred Tax (2013 - 2023)

Protara Therapeutics (TARA) has 7 years of Long-Term Deferred Tax data on file, last reported at $54.3 million in Q4 2023.

• On a quarterly basis, Long-Term Deferred Tax rose 3574.22% year-over-year to $54.3 million in Q4 2023; TTM through Dec 2023 was $54.3 million, a 3574.22% increase from a year earlier, with the FY2023 full-year figure at $54.3 million, up 3574.22% from the prior year.
• Long-Term Deferred Tax for Q4 2023 stood at $54.3 million, up from $1.5 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for TARA reached as high as $54.3 million in Q4 2023 and fell as low as $322000.0 in Q4 2020.
• Historically, Long-Term Deferred Tax has averaged $16.7 million across 5 years, with a median of $4.2 million in 2019.
• Across the five-year window, Long-Term Deferred Tax jumped 7151.55% in 2021 and sank 93.67% in 2022, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $4.2 million in 2019, then tumbled by 92.29% to $322000.0 in 2020, then soared by 7151.55% to $23.3 million in 2021, then sank by 93.67% to $1.5 million in 2022, then soared by 3574.22% to $54.3 million in 2023.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $54.3 million in Q4 2023, $1.5 million in Q4 2022, and $23.3 million in Q4 2021.